Por: Portland Press Herald Health September 28, 2022
An experimental Alzheimer’s drug slowed cognitive and functional decline by 27 percent in a closely watched clinical trial, the sponsors of the medication said Tuesday, increasing the therapy’s chance for approval as soon as early next year. Japanese drugmaker Eisai and its American partner, Biogen, in a news release said the slowing of deterioration, compared with a placebo, was “highly statistically significant.” They said the drug,... + full article
The Boston Globe USA Business September 28, 2022
Biogen and its partner Eisai said Tuesday night that their experimental Alzheimer’s disease therapy successfully slowed the memory-robbing condition in a large clinical trial. The results set the stage for potential approval of the drug next year.Although far from a cure, the... + más
Alzheimer's drug shows promise in early results of study | WPLG Local 10
Alzheimer's drug shows promise in early results of study | ABC News
CNN USA Health September 28, 2022
CNN — A monoclonal antibody treatment for Alzheimer’s disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday. The drug, tested in a Phase 3 global clinical trial, also met all secondary... + más
New test can detect plaques early in the disease: Alzheimer's Q&A | The Advocate
Experimental Alzheimer’s drug slows cognitive decline in trial, firms say | Portland Press Herald
Newsweek USA Health September 24, 2022
The Alzheimer's Association defines Alzheimer's as a brain disease that causes a slow decline in memory, thinking and reasoning skills. Dementia refers to the symptoms of Alzheimer's that can worsen over time.They predict that by 2050, the number of people aged 65... + más
COVID-19 in seniors linked to increased Alzheimer’s risk, study finds | Portland Press Herald
There's a growing dementia crisis in the veteran community: Alzheimer's Q&A | The Advocate
Portland Press Herald USA Health September 24, 2022
A study using the electronic health records of more than 6 million Americans over age 65 found that those who had COVID-19 ran a greater risk of receiving a new diagnosis of Alzheimer’s disease within a year. The study, led by researchers at Case Western Reserve University... + más
How To Spot The Early Signs Of Alzheimer's | Newsweek
The Advocate USA Health September 17, 2022
What is the Lumipulse test for Alzheimer’s disease?In May, the U.S. Food and Drug Administration permitted marketing of the Lumipulse (G B-Amyloid Ratio [1-42/1-40]) test to Fujirebio Diagnostics, Inc. of Malvern, Pennsylvania. The test, which was granted Breakthrough Device... + más
Variety of factors play a role in the development of Alzheimer's | The Advocate
Alzheimer's Q&A: Sildenafil has potential as Alzheimer's drug | The Advocate
What is meant by cognitive reserve?Cognitive reserve is the mind’s resistance to damage to the brain.It is an evidence-based idea proposed by Columbia University neuropsychologist Dr. Yaakov Stern in the mid-1990s which described individuals with no apparent symptoms of... + más
How do you assess the risk of Alzheimer’s disease?Alzheimer’s disease is the only disease in the top 10 causes of death in the United States that cannot be prevented, slowed, or cured. It is not fully understood what causes the disease, but probable causes could be linked to... + más
Here's how to protect patients from scammers: Alzheimer's Q&A | The Advocate
About iurex | Privacy Policy | Disclaimer |